Electrocore LLC Cash Flow Conversion Efficiency
Electrocore LLC cash flow conversion efficiency. Based on the latest financial reports, Electrocore LLC (ECOR) has a cash flow conversion efficiency ratio of 2.339x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.53 Million) by net assets ($-2.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Electrocore LLC (2016–2025)
Cash flow conversion efficiency of Electrocore LLC from 2016 to 2025. This chart illustrates how Electrocore LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Electrocore LLC share price for real-time trading data and today's change.
Electrocore LLC Cash Flow Conversion Ratio Explained
Electrocore LLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Electrocore LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Electrocore LLC ranked by their cash flow conversion efficiency. Also see Electrocore LLC (ECOR) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MasterBeef Group Ordinary Shares
NASDAQ:MB
|
-0.394x |
|
Frontier Lithium Inc
V:FL
|
1.300x |
|
Alterity Therapeutics Limited
F:PBN
|
-0.093x |
|
KPS Corporation
KQ:256940
|
-0.036x |
|
Cauldron Energy Ltd
AU:CXU
|
-0.606x |
|
Johnson Chemical Pharmaceutical Works Co Ltd
TWO:4747
|
0.008x |
|
Austral Gold Ltd
V:AGLD
|
0.084x |
|
High Tech Pharm Co. Ltd
KQ:106190
|
0.052x |
Annual Cash Flow Conversion Efficiency for Electrocore LLC (2016–2025)
The table below shows the annual cash flow conversion efficiency of Electrocore LLC from 2016 to 2025. Review ECOR free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.71 Million | $-8.19 Million | 4.791x | +620.15% |
| 2024-12-31 | $7.54 Million | $-6.95 Million | -0.921x | +53.27% |
| 2023-12-31 | $7.44 Million | $-14.67 Million | -1.971x | -102.32% |
| 2022-12-31 | $17.09 Million | $-16.64 Million | -0.974x | -162.00% |
| 2021-12-31 | $36.65 Million | $-13.63 Million | -0.372x | +56.15% |
| 2020-12-31 | $23.64 Million | $-20.05 Million | -0.848x | +53.15% |
| 2019-12-31 | $24.90 Million | $-45.07 Million | -1.810x | -154.30% |
| 2018-12-31 | $66.19 Million | $-47.11 Million | -0.712x | -351.42% |
| 2017-12-31 | $-89.47 Million | $-25.33 Million | 0.283x | +30.69% |
| 2016-12-31 | $-61.05 Million | $-13.23 Million | 0.217x | -- |
About Electrocore LLC
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic… Read more